Role of Low Frequency Repetitive Trans Cranial Magnetic Stimulation in Drug Resistant Epilepsy Clinical, Laboratory and Neurophysiology Study | ||
International Journal of Medical Arts | ||
Articles in Press, Accepted Manuscript, Available Online from 29 September 2025 | ||
Document Type: Original Article | ||
DOI: 10.21608/ijma.2025.390893.2195 | ||
Authors | ||
Asmaa Mohamed Abd Elwaged* 1; Hoda M Masoud1; Rasha El-bialy Elsharkawy1; Sarah Younes Abdelaziz2 | ||
1Department of Neurology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt. | ||
2Department of Clinical Pathology, Faculty of Medicine for Girls, Cairo, Egypt. | ||
Abstract | ||
Background Drug-resistant epilepsy (DRE) poses significant challenges in management, affecting a huge number of epileptic patients despite the availability of antiepileptic medications. This study investigates the efficacy of Low Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) as a therapeutic technique for DRE. Objective To evaluate the impact of rTMS on seizure frequency, severity, and associated biomarkers in patients with DRE. Methods A total of 45 participants were enrolled, divided into two groups: 23 cases receiving active rTMS and 22 sham controls. The study employed a randomized, double-blind design. Seizure frequency and severity were assessed using the Chalfont Seizure Severity Scale (CSSS) before and six weeks’ post-intervention Results The active rTMS group demonstrated a significant decrease in seizure severity (mean change: 32.39 ± 9.10, p < 0.001) and frequency (mean change: 8.00 ± 2.40, p < 0.001) compared to the sham group. Additionally, HMGB1 levels decreased significantly in the rTMS group (mean change: 11.25 ± 1.72, p < 0.001), while the sham group showed a lesser reduction (mean change: 5.36 ± 1.39, p = 0.037). Correlation analysis revealed a significant relationship between the reduction in seizure severity and HMGB1 levels (r = 0.509, p = 0.006). Conclusion Low-frequency rTMS effectively reduces seizure frequency and severity in patients with DRE. The findings suggest a potential biomarker (HMGB1) associated with treatment response, warranting further investigation into the mechanisms underlying rTMS efficacy in epilepsy management. | ||
Keywords | ||
psychology; neurology; neurosuregry | ||
Statistics Article View: 39 |